Our data suggest that PD-L1-targeted therapy might be a reasonable therapeutic strategy for NSCLC because PD-L1 is regulated by the miR-197/CKS1B/STAT3-mediated signaling cascade. The gene discussed is CKS1B; the disease is non-small cell lung carcinoma.